These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 17332279)

  • 1. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
    Ratnam K; Low JA
    Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical development of PARP inhibitors].
    Toyoda M; Minami H
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):519-24. PubMed ID: 22504675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
    Smith LM; Willmore E; Austin CA; Curtin NJ
    Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward specific functions of poly(ADP-ribose) polymerase-2.
    Yélamos J; Schreiber V; Dantzer F
    Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
    Jagtap P; Szabó C
    Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential contribution of poly(ADP-ribose)polymerase-1 and -2 (PARP-1 and -2) to the poly(ADP-ribosyl)ation reaction in rat primary spermatocytes.
    Tramontano F; Malanga M; Quesada P
    Mol Hum Reprod; 2007 Nov; 13(11):821-8. PubMed ID: 17766683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
    Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
    J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly ADP-ribose polymerase-1 and health.
    Kirkland JB
    Exp Biol Med (Maywood); 2010 May; 235(5):561-8. PubMed ID: 20463295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
    Putt KS; Hergenrother PJ
    Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.